Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).

ICD programming. Indian Heart J (2013) 2.00

SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death. Heart Rhythm (2015) 1.47

Rapid rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship of rapid rate nonsustained ventricular tachycardia to outcomes in the SCD-HeFT study. J Am Coll Cardiol (2013) 1.05

The subcutaneous ICD-current evidence and challenges. Cardiovasc Diagn Ther (2014) 0.97

A systematic review of the association between obstructive sleep apnea and ventricular arrhythmias. J Clin Sleep Med (2014) 0.77

Japan Implantable Devices in Coronary Artery Disease (JID-CAD) study design. J Arrhythm (2014) 0.76

Early experience with the subcutaneous ICD. Curr Cardiol Rep (2014) 0.76

Reply: rapid rate nonsustained ventricular tachycardia found on ICD interrogation: relationship of RR-NSVT to outcomes in the SCD-HeFT trial. J Am Coll Cardiol (2013) 0.75

Trends and determinant factors in the use of cardiac resynchronization therapy devices in Japan: Analysis of the Japan cardiac device treatment registry database. J Arrhythm (2016) 0.75

Mortality and predictors of appropriate implantable cardioverter defibrillator therapy in Japanese patients with Multicenter Automatic Defibrillator Implantation Trial II criteria. J Arrhythm (2016) 0.75

Improve the prevention of sudden cardiac arrest in emerging countries: the Improve SCA clinical study design. Europace (2015) 0.75

Novel Endpoints for Heart Failure Clinical Trials. Curr Heart Fail Rep (2017) 0.75

Effect of supplemented intake of omega-3 fatty acids on arrhythmias in patients with ICD: fish oil therapy may reduce ventricular arrhythmia. J Interv Card Electrophysiol (2017) 0.75

Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med (2005) 27.36

Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med (2012) 8.84

A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol (1989) 5.50

Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med (2008) 5.13

Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol (2008) 4.63

Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation (2004) 3.83

Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol (2008) 2.10

Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA-GEMA Investigators. Circulation (1996) 1.92

A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: the RELEVANT [Role of long dEtection window programming in patients with LEft VentriculAr dysfunction, Non-ischemic eTiology in primary prevention treated with a biventricular ICD] study. Eur Heart J (2009) 1.89

Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. J Cardiovasc Electrophysiol (2004) 1.44

Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Circulation (2000) 1.06

Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. Department of Veterans Affairs CHF STAT Investigators. J Am Coll Cardiol (1998) 1.03

Meta-analysis of effect of statin treatment on risk of sudden death. Am J Cardiol (2007) 1.01

Differences in inducibility and prognosis of in-hospital versus out-of-hospital identified nonsustained ventricular tachycardia in patients with coronary artery disease: clinical and trial design implications. J Am Coll Cardiol (2001) 0.95

Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail (2008) 0.94

Nonsustained ventricular tachycardia in the setting of acute myocardial infarction: tachycardia characteristics and their prognostic implications. Circulation (1998) 0.92

Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med (2005) 27.36

Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med (2011) 11.99

Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med (2011) 10.29

Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74

Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med (2015) 8.70

Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med (2012) 8.28

Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81

Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med (2009) 7.71

Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med (2011) 6.65

Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 6.36

Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17

Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA (2013) 5.31

Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation (2008) 5.15

Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med (2008) 5.13

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA (2013) 4.85

Home use of automated external defibrillators for sudden cardiac arrest. N Engl J Med (2008) 4.64

ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation (2002) 4.56

ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol (2002) 4.48

A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med (2002) 4.42

Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med (2008) 4.33

Music, imagery, touch, and prayer as adjuncts to interventional cardiac care: the Monitoring and Actualisation of Noetic Trainings (MANTRA) II randomised study. Lancet (2005) 4.29

Depression as a risk factor for mortality after coronary artery bypass surgery. Lancet (2003) 4.21

Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation (2003) 3.97

Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med (2005) 3.83

Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation (2003) 3.57

Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy. Circulation (2008) 3.54

The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg (2007) 3.45

Effect of an implantable gentamicin-collagen sponge on sternal wound infections following cardiac surgery: a randomized trial. JAMA (2010) 3.39

Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med (2002) 3.35

Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale. Am Heart J (2007) 3.34

Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol (2013) 3.15

Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation (2013) 3.14

Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trial. Ann Intern Med (2013) 3.08

Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). J Subst Abuse Treat (2003) 2.93

Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol (2007) 2.90

Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation (2006) 2.60

Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation (2009) 2.57

Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med (2009) 2.49

International differences in evolution of early discharge after acute myocardial infarction. Lancet (2004) 2.47

Sex Differences in Demographics, Risk Factors, Presentation, and Noninvasive Testing in Stable Outpatients With Suspected Coronary Artery Disease: Insights From the PROMISE Trial. JACC Cardiovasc Imaging (2016) 2.36

Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation (2009) 2.34

The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. J Am Coll Cardiol (2004) 2.34

Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION predictive risk score model. Circ Heart Fail (2011) 2.28

Central nervous system injury associated with cardiac surgery. Lancet (2006) 2.27

Design and methodology of the Occluded Artery Trial (OAT). Am Heart J (2005) 2.26

Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. Heart Rhythm (2013) 2.22

Evolution of the coronary care unit: clinical characteristics and temporal trends in healthcare delivery and outcomes. Crit Care Med (2010) 2.19

Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol (2013) 2.17

Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. J Thorac Cardiovasc Surg (2012) 2.10

Design of the Trial to Assess Chelation Therapy (TACT). Am Heart J (2012) 2.09

Cardiac resynchronization therapy: Part 1--issues before device implantation. J Am Coll Cardiol (2005) 2.06

A critic's assessment of our approach to cardiac arrest. N Engl J Med (2011) 2.04

No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). J Am Coll Cardiol (2008) 2.03

Initial Experience of an Anesthesiology-based Service for Perioperative Management of Pacemakers and Implantable Cardioverter Defibrillators. Anesthesiology (2015) 1.99